Erythropoietin, Magnesium sulfate and Hypothermia for Hypoxic-Ischemic Encephalopathy

Erythropoietin, Magnesium sulfate and Hypothermia for Hypoxic-Ischemic Encephalopathy - Erythropoietin, Magnesium sulfate and Hypothermia for Hypoxic-Ischemic Encephalopathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032627

Enrollment

Registered

2018-05-18

Start date

2013-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal hypoxic-ischemic encephalopathy

Interventions

Recombinant human erythropoietin 300 U/kg every other day for 2 weeks Mugnesium sulfate 250mg/kg for 3 days Hypothermia 33.5 degrees C for 72 hours

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network hypothermia trial.

Exclusion criteria

Exclusion criteria: Exclusion criteria by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network hypothermia trial.

Design outcomes

Primary

Measure	Time frame
Serious advverse evvents	—

Secondary

Measure	Time frame
BP and HR at 0-7 days of age Motality and morbidity at 0-7 days and 18 months of age Neurodevelopmental outocome at 18 months of age	—

Countries

Japan

Contacts

Public ContactHiroyuki Ichiba

Osaka City General Hospital Department of Neonatology

h-ichiba@med.osaka-cu.ac.jp0669291221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026